Introduction {#Sec1}
============

Posterior reversible encephalopathy syndrome (PRES) is a clinical entity characterized by acute neurological symptoms such as severe headache, seizures, and visual disturbance, and by reversible lesion hyper-intensity on FLAIR and T2-weighted sequences on brain magnetic resonance (MR) images, especially in the bilateral occipital and parietal lobes \[[@CR1], [@CR2]\]. PRES is thought to arise from vascular endothelial injury due to cytotoxic agents or acute systemic hypertension \[[@CR2]\]. Recently, there has been an increase in the number of reports about PRES associated with not only conventional chemotherapeutic agents, but also new molecular targeted drugs, particularly angiogenesis inhibitors, which may cause systemic hypertension as an adverse effect \[[@CR3], [@CR4]\]. Pazopanib is an oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit, and is approved for use in advanced renal cell carcinoma and soft-tissue sarcoma \[[@CR5]--[@CR7]\]. Five cases of PRES induced by pazopanib for renal cell carcinoma have been reported \[[@CR8]--[@CR12]\]. However, no case of PRES due to pazopanib for soft-tissue sarcoma has been reported in the English literature. Here, we present a patient of this type and describe her clinical course.

Case report {#Sec2}
===========

We report a 49-year-old woman with retroperitoneal soft-tissue sarcoma. She had no previous history of systemic hypertension, renal dysfunction, or autoimmune disease. She was diagnosed by computed tomography (CT)-guided needle biopsy of the tumor. Gemcitabine and docetaxel were administered as initial treatment, but the disease progressed after five cycles of chemotherapy. Ifosfamide and adriamycin were administered as a second-line treatment for 8 months, achieving partial response as a best response, but were stopped due to severe and prolonged myelosuppression. Three months later, pazopanib at 800 mg/day was administered as a third-line treatment at relapse. She had taken fentanyl transdermally and a sublingual tablet as pain relief, along with proton pump inhibitors, sleep inducers, and an anti-emetic drug on a regular basis. Twenty-eight days later, the dose of pazopanib was reduced from 800 to 600 mg/day because of nausea and anorexia. Another two days later, CT examination revealed that she had achieved a partial response. However, another eight days later, she was admitted to our hospital with severe headache, nausea, and vomiting. Her blood pressure was 154/87 mmHg on admission. Blood tests including complete blood count, blood chemistry, and coagulation showed no abnormal findings other than hyponatremia (129 mEq/L). Renal function was in the normal range (estimated GFR: 70.4 ml/min/1.73m^2^). Urine analysis showed no proteinuria. Brain MR images without contrast agent showed normal findings. Supportive care did not improve her symptoms. The next day, she suddenly presented consciousness deterioration (Glasgow Coma Scale 13 points) and visual disturbance along with severe systemic hypertension (201/108 mmHg). Brain MR images revealed hyper-intense signals in the bilateral occipital lobes and left thalamus on FLAIR sequences, but no lesions on a diffusion-weighted image (DWI) (Fig. [1](#Fig1){ref-type="fig"}). Under a diagnosis of PRES, she was treated with anti-convulsant (fosphenytoin sodium hydrate at 375 mg/day), betamethasone (4 mg/day), osmotic diuretics (glycerol at 200 ml/day), and anti-hypertensive drug (nicardipine, continuous intravenous injection). Her systolic blood pressure could be controlled below 130 mmHg. At the same time, pazopanib was discontinued. Her symptoms gradually improved and disappeared on the fifth hospital day. She was discharged on the seventh hospital day. Two weeks later, brain MR images revealed complete disappearance of the hyper-intense signals on FLAIR sequence (Fig. [1](#Fig1){ref-type="fig"}). Then, oral administration of pazopanib at 400 mg/day was again applied along with the anti-hypertensive drug. Ultimately, the dose was escalated to 600 mg/day and there was no recurrence of PRES under good blood pressure control. Unfortunately, the patient died 9 months after restarting pazopanib because of progression of the primary tumor.Fig. 1FLAIR (**a**) and DWI (**b**) on brain MR images at onset of PRES. FLAIR (**c**) and DWI (**d**) on brain MR images of the same patient after 3 weeks

Discussion {#Sec3}
==========

Soft-tissue sarcomas are rare malignant tumors derived from mesodermal tissues such as skeletal muscle, adipose, and fibrous tissue \[[@CR13]\]. Pazopanib was approved for treatment of metastatic soft-tissue sarcomas by the US Food and Drug Administration based on a phase III trial (PALETTE) in 2012. In the PALETTE study, pazopanib significantly improved the progression-free survival (PFS) of patients with soft-tissue sarcomas. On the other hand, it caused systemic hypertension as an adverse event in 41% of the patients (CTCAE Grade 3: 7%) \[[@CR7]\]. Acute and severe systemic hypertension may cause vasodilation and disruption of cerebral autoregulation, resulting in breakdown of the blood--brain barrier \[[@CR2]\]. In addition, pazopanib inhibits the VEGF and PDGF pathway, which may lead to vascular endothelial damage \[[@CR14]\]. These pathophysiological changes might cause vascular leaks and cerebral edema, resulting in PRES due to pazopanib. The case reports of PRES induced by pazopanib are compiled in Table [1](#Tab1){ref-type="table"} \[[@CR8]--[@CR12]\]. All patients developed PRES with marked systemic hypertension after more than a week of pazopanib administration. Brain edema occurred mostly in bilateral occipital lobes, not in cerebellum or brain stem. Most patients recovered within a week by withdrawal of pazopanib and anti-hypertension therapy. These features are consistent with our case of soft-tissue sarcoma.Table 1Characteristics of patients with PRES induced by pazopanibAuthorsPrimary tumorAge (years)SexDose of pazopanibDuration from onset of PRES to starting pazopanibSymptomsLocationBP at PRES presentationTreatmentOutcomeTime to resolutionChelis et al. \[[@CR8]\]RCC40F800 mg/d21 daysheadache, seizure, vision disturbancebi-frontal, parietal, occipital lobes165/105phenytoin, mannitol, antihypertensive agentsresolved1 dayFoerster et al. \[[@CR9]\]RCC62F800 mg/d2 monthsheadache, seizure, left arm paresis, gait instability, nausea, vomitingleft parietal lobe\> 300diazepam, levetiracetam, anti-hypertensive agentsresolved6 daysAsaithambi et al. \[[@CR10]\]RCC76M800 mg/d1 monthheadache, vision disturbance, vomiting, disorientationbi-temporal, parietal, occipital lobes219/155anti-hypertensive agentsresolved2 daysMiaris et al. ([@CR11])RCC56F800 mg/d9 daysheadache, nausea, vomiting, dizziness, gait instabilitybi-frontal, parietal, occipital lobes165/ 95levetiracetam, antihypertensive agentsresolved3 daysMiller-Patterson et al. \[[@CR12]\]RCC69Fnot shown3 weeksheadache, left-sided weaknessbi-occipital lobes (combined hemorrhage)204/92anti-hypertensive agentsresolvednot shownPresent case (2017)Softtissue sarcoma52F800 mg/d38 daysheadache, nausea, seizure, vision disturbancebi-occipital lobes, left thalamus201/108osmotic diuretics, betamethasone, fosphenytoin, antihypertensive agentsresolved5 days

PRES is not always completely reversible and its associated mortality rate has been reported to be about 3%--6% \[[@CR2]\]. Elimination of the causative factors at an early stage is critical to prevent poor outcomes \[[@CR2]\]. Further, in cases of PRES associated with systemic hypertension, a general consensus has been reached about the importance of prompt anti-hypertension therapy. An initial goal of reducing blood pressure by 25% within several hours of the onset of PRES using continuous intravenous administration of anti-hypertensive agents should be set \[[@CR15]\]. In fact, in our case as well, the neurological deficits dramatically improved with the control of blood pressure, suggesting the efficacy of anti-hypertensive therapy for PRES.

As for another angiogenesis inhibitor, bevacizumab (BV), sub-analysis of a phase III trial of BV plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma showed that patients who developed systemic hypertension by BV exhibited significant improvements in PFS and overall survival compared with patients without systemic hypertension \[[@CR16]\]. The complication of systemic hypertension is not a contraindication for using BV or pazopanib. Indeed, as in our case, Lou et al. reported a patient with glioblastoma (GBM) who developed PRES induced by BV, restarted BV from a low dose under good control of blood pressure, and maintained a clinical stable condition for 4 months without PRES recurrence \[[@CR17]\]. As there are insufficient data to determine whether readministering pazopanib is safe, special care for patients is necessary. However, since the treatment options are very limited for rare cancers such as sarcoma or GBM, readministering angiogenesis inhibitors may be acceptable under appropriate management. We hope that therapeutic guidelines for PRES will contribute to the safer and more effective management of patients treated with new drugs by accumulation of more data in future.
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